Interim Results of Trastuzumab Deruxtecan in HER2-Mutated Metastatic NSCLC
Posted: Tuesday, July 7, 2020
Treatment with fam-trastuzumab deruxtecan-nxki (T-DXd) demonstrated clinical activity in patients with metastatic, HER2-mutated, nonsquamous non–small cell lung cancer (NSCLC), according to the ongoing DESTINY-Lung01 study. Egbert F. Smit, MD, PhD, of the Netherlands Cancer Institute, Amsterdam, and colleagues reported that T-DXd—an antibody-drug conjugate composed of an anti-HER2 antibody, cleavable tetrapeptide-based linker, and topoisomerase I inhibitor payload—appears to produce durable responses and a high objective response rate. The interim results of the phase II trial were presented during the ASCO20 Virtual Scientific Program (Abstract 9504).
At a median follow-up of 8 months, 42 patients had received T-DXd at 6.4 mg/kg every 3 weeks. The median patient age was 63 years, and approximately half (45.2%) of patients had central nervous system metastases. Most patients (90.5%) had prior platinum-based chemotherapy, and 54.8% had anti–PD-1 or anti–PD-L1 treatment.
The confirmed objective response rate was 61.9%, and the median duration of response was not reached. At the interim cutoff, 45.2% of patients remained on treatment, including 16 of 26 responders. The researchers estimated the median progression-free survival was 14 months.
All patients experienced treatment-emergent adverse events. More than half (64.3%) had grade ≥ 3 events, including decreased neutrophil count (26.2%) and anemia (16.7%). There were also five cases of grade 2 drug-related interstitial lung disease. Treatment-emergent adverse events led to dose interruption in 59.5% of patients, dose reduction in 38.1%, and treatment discontinuation in 23.8%.
Disclosure: For full disclosures of the study authors, visit coi.asco.org.
